Objectives Tristetraprolin (TTP), a negative regulator of many pro-inflammatory genes, is strongly expressed in rheumatoid synovial cells. The mitogen-activated protein kinase (MAPK) p38 pathway mediates the inactivation of TTP via phosphorylation of two serine residues. We wished to test the hypothesis that these phosphorylations contribute to the development of inflammatory arthritis, and that, conversely, joint inflammation may be inhibited by promoting the dephosphorylation and activation of TTP.
Methods The expression of TTP and its relationship with MAPK p38 activity were examined in non-inflamed and rheumatoid arthritis (RA) synovial tissue. Experimental arthritis was induced in a genetically modified mouse strain, in which endogenous TTP cannot be phosphorylated and inactivated. In vitro and in vivo experiments were performed to test anti-inflammatory effects of compounds that activate the protein phosphatase 2A (PP2A) and promote dephosphorylation of TTP.
Results TTP expression was significantly higher in RA than non-inflamed synovium, detected in macrophages, vascular endothelial cells and some fibroblasts and co-localised with MAPK p38 activation. Substitution of TTP phosphorylation sites conferred dramatic protection against inflammatory arthritis in mice. Two distinct PP2A agonists also reduced inflammation and prevented bone erosion. In vitro anti-inflammatory effects of PP2A agonism were mediated by TTP activation.
Conclusions The phosphorylation state of TTP is a critical determinant of inflammatory responses, and a tractable target for novel anti-inflammatory treatments.
- Rheumatoid Arthritis
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Statistics from Altmetric.com
The mitogen-activated protein kinase (MAPK) p38 signalling pathway positively regulates the expression of many inflammatory mediators, and is thought to play a key role in the pathogenesis of rheumatoid arthritis (RA).1–3 Although activation of all four MAPK p38 isoforms (α, β, γ and δ) has been detected in RA synovial cells,3 genetic and pharmacological evidence suggests that MAPK p38α is likely to be the most important contributor to joint inflammation and bone erosion.1 ,2 Prototypical inhibitors of MAPK p38α and β were discovered in a high-throughput screen for compounds that reduced the expression of tumour necrosis factor α (TNFα) in activated macrophages.4 Increasingly specific and potent inhibitors were later generated by several pharmaceutical companies. These compounds reduced the expression of many inflammatory mediators and they also demonstrated therapeutic effects in experimental models of RA. Therefore, they were considered promising as disease-modifying antirheumatic drugs,2 ,5 and several entered clinical trials in RA. Yet no MAPK p38 inhibitor has received regulatory approval, seemingly due to dose-limiting hepatotoxicity and lack of sustained anti-inflammatory efficacy.6 The following questions arise: Why, contrary to expectation, did inhibition of MAPK p38 fail to achieve lasting therapeutic effects? How does the MAPK p38 pathway regulate inflammatory responses? Can our understanding of the pathway still be leveraged to devise more effective anti-inflammatory strategies?
Many of the effects of MAPK p38 on the expression of pro-inflammatory genes are mediated by the mRNA-binding protein tristetraprolin (TTP). TTP binds to adenosine/uridine-rich elements (AREs) in the 3′ untranslated regions of target mRNAs. It then recruits deadenylases, which shorten the poly(A) tail, resulting in suppression of translation and rapid degradation of the mRNA.7 ,8 Disruption of the mouse TTP gene (formally Zfp36) results in a severe inflammatory syndrome, including an erosive arthritis that resembles RA.8 ,9 Dysregulated expression of TNFα by macrophages is necessary but not sufficient for the RA-like phenotype.10 ,11 Either disruption of the Zfp36 gene or targeted deletion of the Tnf ARE renders TNF biosynthesis insensitive to MAPK p38 inhibition.12 ,13 This indicates that MAPK p38 enhances TNF expression by inactivating the anti-inflammatory protein TTP.
Several groups have characterised the mechanism of regulation of TTP expression and function.14–20 MAPK p38 is activated in response to various pro-inflammatory stimuli, and in turn activates the downstream kinase MAPK-activated protein kinase 2 (MK2). MK2 phosphorylates serines 52 and 178 of murine TTP (60 and 186 of human TTP).21 ,22 These phosphorylations have seemingly contradictory effects on the expression and activity of TTP. First, they protect it from destruction by the proteasome.17 ,18 ,23 Second, they inactivate it by impairing its ability to recruit deadenylases,16 ,24 ,25 reducing its affinity for RNA26 or both. We recently described a knockin mouse strain (Zfp36aa/aa), in which serine 52 and 178 codons of the endogenous Zfp36 locus were substituted by alanine codons. These mice express a mutant form of TTP (known as TTP-aa), which cannot be phosphorylated by MK2. It was expressed at low levels, yet functioned as a potent suppressor of many inflammatory mediators.15 Furthermore, the inflammatory consequences of dysregulated MAPK p38 signalling were mitigated by substitution of the two TTP phosphorylation sites.20
A result of the coupled stabilisation and inactivation of TTP is that MAPK p38 activation promotes the accumulation of TTP in its inactive form. As the activity of the MAPK p38 pathway declines, TTP is dephosphorylated by protein phosphatase 2A (PP2A),27 converting it to an active form that promotes degradation of target mRNAs. Because of this complex regulation of expression and activity of TTP, acute and chronic inhibition of MAPK p38 have very different effects on inflammatory mRNA stability.28 Addition of a MAPK p38 inhibitor after a pro-inflammatory stimulus causes activation of pre-existing TTP and enhanced degradation of target mRNAs. In contrast, prolonged inhibition of MAPK p38 prevents the accumulation of TTP protein, and target mRNAs consequently remain stable. This phenomenon may contribute to the transient anti-inflammatory effects of MAPK p38 inhibitors in clinical trials.1 ,29 Additional mechanisms of escape from anti-inflammatory effects of the inhibitors have also been suggested,1 ,29 mostly involving the disruption of MAPK p38-dependent negative feedback loops.
Aberrant activation of MAPK p38 signalling in the RA synovium has been described.3 TTP protein has been detected in the RA synovium,30 but the cells expressing it were not identified, and its relationship with disease state or with MAPK p38 activity was not explored. Here, we wished to investigate whether inactivation of TTP via the phosphorylation of serines 52 and 178 contributes to synovial inflammation and bone erosion, and whether those pathological processes might be prevented by re-activation of TTP.
Detailed methods are provided in the online supplementary material.
Synovial tissue biopsies were obtained from patients undergoing ultrasound-guided arthroscopy. Samples were designated ‘normal’ if histological inspection revealed no macroscopic evidence of inflammation, and absence of inflammatory pathology was confirmed by clinical follow-up. All participants gave written informed consent. The study was approved by the National Research Ethics Service Committee West Midlands.
All mice were maintained and housed under conventional conditions in the Biomedical Services Unit at the University of Birmingham. Experimental protocols were performed under Home Office guidelines and project licence 40/8003. Zfp36aa/aa15 and TNFΔARE12 strains have been previously described.
Clinical scoring, histological analyses and scoring of bone erosion were performed by ‘blinded’ observers. Statistical analysis was performed by Mann-Whitney U test using Prism V.6.0 (GraphPad).
Expression of TTP in the rheumatoid synovium
Expression of TTP protein was significantly elevated in synovial tissue of patients with RA compared with non-inflamed controls (figure 1A, B). TTP was present in several cell types, with strongest staining in CD68+ macrophages. The glycoproteins podoplanin (PDPN) and CD248 are thought to identify discrete populations of fibroblasts in the rheumatoid synovium.31 There was little co-localisation of PDPN with TTP. Instead, PDPN+ fibroblasts were interspersed with TTP+ CD68+ macrophages (figure 1C). A subset of CD248+ cells expressed TTP (figure 1D). There was also strong staining for TTP in CD31+ vascular endothelial cells (figure 1E, see online supplementary figure S2). TTP protein was co-localised with activated MK2 in the cytoplasm of many macrophages (figure 1F). Antibody controls and single colour images are in online supplementary figures S1 and S2.
Blockade of TTP phosphorylation is protective in experimental models of inflammation and inflammatory arthritis
To test the hypothesis that phosphorylation of TTP favours joint inflammation, we employed Zfp36aa/aa mice.15 Initially, responses were tested in the zymosan-induced air pouch inflammation model, which recapitulates aspects of the localised synovial inflammation observed in RA.32 Injection of zymosan into air pouches of Zfp36+/+ mice rapidly elevated levels of CXCL1 (chemokine (C-X-C motif) ligand 1), CXCL2, interleukin (IL)-6 and TNF in the exudate fluid. These cytokines are known to be regulated by TTP,8 ,15 and were all underexpressed in exudate fluid of Zfp36aa/aa mice at 1 and 4 hours time points (figure 2A). In contrast, CCL5 was strongly elevated at 4 hours but not significantly different between Zfp36+/+ and Zfp36aa/aa mice. Ccl5 mRNA does not possess an ARE and has not been implicated as a TTP target. This result indicates that cytokine responses are selectively rather than globally affected by the TTP mutation. Zymosan also promoted an influx of leucocytes (figure 2B), the majority of which were neutrophils (data not shown). Cellular infiltration was decreased by 50% in Zfp36aa/aa mice.
Serum transfer-induced arthritis (STIA)33 was attempted next. All Zfp36+/+ mice developed arthritis after injection of arthritogenic K/BxN serum (figure 3A), with transient weight loss (figure 3B) and swelling of ankles and footpads (figure 3C). STIA was associated with increased numbers of CD45− cells in knee joints due to stromal cell proliferation (figure 3D); marked infiltration of CD45+ cells, the majority of which were neutrophils and macrophages (figure 3D) and elevated expression of the pro-inflammatory mRNAs Il1b, Il6, Cxcl1 and Cxcl2 (figure 3E). These changes were absent or almost absent from serum-injected Zfp36aa/aa mice.
In Zfp36+/+ mice, K/BxN serum induced leucocytic infiltration of joints and skin, synovial hyperplasia and pannus formation (figure 4A), loss of articular cartilage (figure 4A, B) and peri-articular erosion of bone (figure 4A, C), which was accompanied by osteoclast activation (figure 4D, E). None of these changes occurred in Zfp36aa/aa mice. Similar experiments have been carried out four times, using three batches of K/BxN serum from two laboratories. Disease penetrance (proportion of mice developing a clinical score >1 for more than three consecutive days) was 100% in Zfp36+/+ mice and 0% in Zfp36aa/aa mice. Cumulative disease severity, calculated as area under the curve (AUC) of the plot of disease score against time, was reduced by 70% in heterozygous Zfp36+/aa mice (AUC of 37.6±14.1, compared with 123.8±7.4 in Zfp36+/+ mice, p<0.01). This finding is consistent with the dominant anti-inflammatory function of the constitutively active form of TTP,15 and suggests that a moderate alteration in the equilibrium between phosphorylated and unphosphorylated TTP has anti-inflammatory consequences.
Roles of stromal and haematopoietic TTP in protection against experimental arthritis
To investigate the functions of TTP in haematopoietic and non-haematopoietic compartments, bone marrow chimaeras were generated between Zfp36+/+ and Zfp36aa/aa mice, and STIA experiments performed. On average, 97% of CD45+ cells in both chimaeras were donor-derived (figure 5A). In Zfp36+/+ mice, STIA developed and resolved over 26 days, while there was no evidence of disease in Zfp36aa/aa mice over the same interval (figure 5B). Despite subtle differences in the timings of disease onset and resolution (figure 5B), neither mice expressing TTP-aa in haematopoietic cells (filled grey symbols) nor in non-haematopoietic cells (open grey symbols) were protected from STIA, at least at the level of macroscopic symptoms (figure 5C). However, the presence of TTP-aa in haematopoietic cells conferred protection against bone erosion (figure 5D, right panels of figure 5E).
The lack of protection from STIA in mice expressing TTP-aa only in the haematopoietic compartment implied that TTP may function in non-haematopoietic cells to inhibit inflammation. Joint stromal cells were isolated from Zfp36+/+ and Zfp36aa/aa mice and challenged with either IL-1β or lipopolysaccharide (LPS; figure 5F). The expression of IL-6, CXCL1 and CXCL2 was significantly decreased in Zfp36aa/aa stromal cells stimulated with either IL-1β or LPS, except in the case of IL-1β-stimulated CXCL1, where the difference of expression did not achieve statistical significance (p=0.06).
Therapeutic targeting of TTP phosphorylation
To investigate whether pharmacological disturbance of the equilibrium between phosphorylation and dephosphorylation of TTP conferred protection against STIA, we used two chemically distinct compounds reported to activate PP2A by disrupting its interactions with inhibitory protein complexes.34 ,35 COG1410, an apolipoprotein E peptide mimetic, exerts protective effects in experimental models of neuroinflammation.36 ,37 AAL(s) is a lipid derivative of the immunosuppressant FTY720 (fingolimod). Unlike its parent compound, it does not influence sphingosine 1 phosphate signalling and has no effects on lymphocyte trafficking. Instead, its anti-inflammatory effects have been attributed to activation of PP2A and subsequently TTP.35 ,38 ,39
C57BL/6 mice were treated with vehicle, COG1410 or AAL(s) from day 2 after the injection of K/BxN serum. Both COG1410 and AAL(s) reduced disease progression (figure 6A), cumulative disease severity (figure 6B) and ankle swelling (figure 6C). AAL(s) significantly decreased the expression of the pro-inflammatory genes Il6 and Cxcl2 in joints (figure 6D). This effect did not reach statistical significance in COG1410-treated mice. Βoth PP2A agonists protected against bone erosion (figure 6E). A control scrambled peptide with the same amino acid composition as COG1410 had no effect on disease progression (see online supplementary figure S3).
In vitro experiments investigating the mechanisms of response to PP2A agonism employed COG1410, which had stronger anti-inflammatory effects in vivo. COG1410 significantly decreased expression of TNF by Zfp36+/+ bone marrow-derived macrophages (BMMs), whereas in Zfp36aa/aa BMMs the expression of TNF was comparatively low, and was not further decreased by COG1410 (figure 6F). COG1410 decreased the expression of wild-type TTP, but did not affect the weak expression of TTP-aa (figure 6G). These observations support the hypothesis that activation of PP2A and dephosphorylation of serines 52 and 178 both activates and destabilises TTP. Effects of COG1410 were also tested in BMMs derived from Tnf-Δare mice, in which the TTP binding site is specifically deleted from Tnf mRNA.12 Elevated expression of TNF in Tnf-Δare BMMs was insensitive to COG1410, whereas the expression of CXCL2 remained sensitive to COG1410 (figure 6H). COG1410 did not influence Akt, extracellular signal-regulated kinase (ERK), MAPK p38 or MK2 phosphorylation in response to LPS (figure 6I). Therefore, in vitro anti-inflammatory effects of COG1410 require an intact TTP binding site within the target mRNA, depend on the ability to modulate TTP phosphorylation state, but do not involve impairment of signalling events upstream of TTP phophorylation. In three independently derived RA synovial fibroblast lines, COG1410 dose-dependently inhibited TNF-induced IL-8 expression (figure 6J). In human monocyte-derived macrophages, COG1410 also decreased the LPS-induced expression of TNF (figure 6K), suggesting that promotion of the dephosphorylation and activation of TTP may also exert anti-inflammatory effects in these cells.
Here and elsewhere,30 ,40 the anti-inflammatory effector protein TTP has been shown to be strongly expressed at sites of active inflammation, including RA synovial lining cells. This prompted the question of “Why TTP is not acting to reduce TNFα expression in rheumatoid synovial macrophages”.30 A likely answer is that aberrant activation of MAPK p38 in the RA synovium leads to the accumulation of TTP in a phosphorylated and inactive form, so that it is incapable of downregulating TNFα and other targets. This conclusion is based on the observations that: (1) TTP expression was higher in inflamed than non-inflamed synovial tissue (figure 1A, B); (2) strong expression coincided with activation of the MAPK p38 pathway (figure 1F); (3) precise, genetically mediated blockade of MAPK p38-dependent phosphorylation of TTP powerfully protected mice against experimental arthritis (figures 3⇑–5). The dramatic, inflammation-resistant phenotype of the genetically modified Zfp36aa/aa mouse in this robust experimental model is, to our knowledge, unprecedented for such a small genetic alteration (substitution of two codons).
Bone marrow chimaera experiments demonstrated that protection from experimental arthritis was dependent on enhanced function of TTP in both haematopoietic and non-haematopoietic compartments (figure 5). This finding is consistent with reports that global Zfp36 gene disruption led to spontaneous inflammatory arthritis,9 whereas myeloid-specific Zfp36 gene disruption did not.10 ,11 It was recently shown that TTP negatively regulates expression of several inflammatory mediators in murine embryonic fibroblasts.41 Here, we show that murine joint fibroblasts containing the constitutively active form of TTP expressed lower amounts of IL-6, CXCL1 and CXCL2 in response to inflammatory stimuli. These attenuated responses of stromal cells may help to explain the delay in onset of arthritis in chimaeras expressing TTP-aa in their non-haematopoietic compartment. TTP protein was detected in a subset of synovial fibroblasts of patients with RA (figure 1). Therefore, it is likely that TTP functions as a suppressor of inflammation in at least some joint fibroblasts. The strong expression of TTP protein in vascular endothelial cells was also striking, and may point to a role in restraint of vascular activation, via downregulation of cytokines, chemokines and/or adhesion molecules.40 ,42 ,43
The bone marrow chimaera experiments also revealed uncoupling between joint inflammation and bone erosion (figure 4). When TTP-aa was present in haematopoietic cells, mice were not protected from macroscopic inflammation, but were strongly protected against bone erosion. Inflammatory osteolysis is dependent on MAPK p38.44 Osteoclast activation and bone erosion were increased in mice lacking the dual specificity phosphatase DUSP1, and therefore having dysregulated MAPK p38 activity.45 In vivo delivery of TTP using an adenoviral vector conferred protection against experimentally induced osteolysis.44 ,46 It is therefore likely that the MAPK p38-TTP pathway controls the differentiation and/or activation of osteoclasts. The absence of a bone phenotype of Zfp36aa/aa mice under resting conditions suggests that such a role would likely be restricted to inflammatory contexts.
We suggest that promoting the dephosphorylation of TTP represents a novel strategy for treatment of chronic inflammatory pathologies such as RA. Potential advantages of this approach are: (1) that it may avoid some of the pitfalls of targeting upstream signalling events; (2) that it requires no assumptions about the factors that drive inflammation or the signalling pathways actually responsible for the phosphorylation and inactivation of TTP in the RA synovium; (3) that it capitalises on the accumulation of TTP at sites of inflammation,30 ,40 a pool of dormant anti-inflammatory effector protein that is ripe for re-activation. This is in keeping with the philosophy of harnessing edogenous off-switches and anti-inflammatory mechanisms, rather than targeting the activators of inflammation.47 Proof of principle is provided by two chemically distinct compounds that are reported to activate PP2A, and which reduce inflammation and bone erosion in an experimental model of RA (figure 6A–E). PP2A is a pleiotropic enzyme complex with multiple substrate phospho-proteins and cellular functions,48 therefore, the mechanism of anti-inflammatory action of PP2A agonists is open to question. Our in vitro data support the concept that activation of PP2A exerts anti-inflammatory effects at least in part via the activation of TTP (figure 6F–I). Future studies will investigate relationships between TTP expression and phosphorylation state, disease activity and response to therapy. More also needs to be known about mechanisms of recognition and dephosphorylation of TTP by PP2A. The data reported here suggest that these will be fruitful areas to explore.
Handling editor Tore K Kvien
Contributors EAR performed experiments, collected and analysed data. AJN, JDO, TC, MLR, TS, JC, TJT and JDT performed experiments and collected data. LVN, SD, HP, NMV, GK, MPV and AF provided essential reagents or clinical material. EAR, CDB, JLD and ARC designed the study and analysed data. ARC wrote the manuscript.
Funding The study was supported by Programme Grant 19614 and ‘RACE’ Rheumatoid Arthritis Centre of Excellence in Pathogenesis Grant 20298, both from Arthritis Research UK. The generation of the Zfp36aa/aa mouse strain was supported by Project Grant G0800207 from the Medical Research Council UK.
Competing interests MPV is a founder, owner and employee of Cognosci, Inc., which holds patents on apoE-mimetics including COG1410.
Patient consent Obtained.
Ethics approval National Research Ethics Committee West Midlands.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.